DalsnaFinance

J&J’s nipocalimab meets primary endpoint in lupus study

Markets Investing.com By Investing.com 03 Jun 2026 04:37 1 min read
J&J’s nipocalimab meets primary endpoint in lupus study

J&J’s nipocalimab meets primary endpoint in lupus study

J&J’s nipocalimab meets primary endpoint in lupus study

Read the full story on Investing.com → Opens the original article on www.investing.com

Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.